Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.

Biemond, I.; Crobach, L. F. S. J.; Jansen, J. B. M. J.; Lamers, C. B. H. W.

doi:10.1111/j.1365-2125.1990.tb03665.x

Cited by 5 publications

(4 citation statements)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other experiences showed significantly higher serum pepsinogen levels after 7 and 14 days therapy with omeprazole 20 mg daily compared with pretreatment values; furthermore, a rapid fall of PGI (within 7 days) to baseline levels after discontinuing antisecretory therapy was observed [9]. Similar results were obtained after omeprazole intake for 3 consecutive days in a regimen of intermittent administration [10]. Although other reports confirmed the decrease of PGI values after interruption of long-term antisecretory therapy, PGI levels were higher than previous therapy [12].…”

Section: Discussionsupporting

confidence: 59%

“…to baseline levels after discontinuing antisecretory treatment [9][10][11][12][13][14][15][16][17][18]. It is generally accepted that serum pepsinogen I (sPGI) reflects gastric acid secretion [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

“…It has been reported that serum pepsinogens levels (sPGI and sPGII), which are predictive of the histological status of the gastric mucosa [5–8], rise during omeprazole and lansoprazole administration and rapidly return to baseline levels after discontinuing antisecretory treatment [9–18]. It is generally accepted that serum pepsinogen I (sPGI) reflects gastric acid secretion [5–7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels

Mario

Ingegnoli

Altavilla

et al. 2005

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

It has been reported in literature that serum pepsinogen levels rise during omeprazole and lansoprazole administration. However, the influence of pantoprazole and esomeprazole on serum pepsinogens levels is still to be assessed. The aim of this study was to evaluate the influence of proton pump inhibitor (PPI) therapy on pepsinogen I (PGI) levels. PGI and gastrin (G17) levels (EIA; Biohit, Helsinki, Finland) in 126 consecutive patients (M 57; F 69, mean age 53, range 15-91), with upper gastrointestinal symptoms at baseline condition and after 2 months of PPI treatment, were evaluated. Patients underwent a therapy schedule based on: omeprazole 20 mg b.i.d. (20 patients), pantoprazole 40 mg b.i.d. (27 patients), esomeprazole 40 mg b.i.d. (29 patients), lansoprazole 30 mg b.i.d. (21 patients) and rabeprazole 20 mg b.i.d. (26 patients) for 2 months. A significant increase in serum PGI (sPGI) levels was found after a 2-month treatment for all five different PPIs: omeprazole, pantoprazole, esomeprazole, lansoprazole and rabeprazole (P < 0.05). The effect of rabeprazole on sPGI was less pronounced as compared with other PPIs, whereas esomeprazole achieved superior sPGI levels, with no overall statistically significant difference among the five groups (P > 0.05). However, a comparison within a single group of PPIs showed a statistical significance when the esomeprazole group was compared with the rabeprazole group (P = 0.007). sPGI levels are significantly influenced by antisecretory therapy, rising under PPI treatment. Moreover, a statistically significant difference in sPGI levels between the rabeprazole and esomeprazole groups has been demonstrated.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels

Mario

Ingegnoli

Altavilla

et al. 2005

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…First, we did not obtain data on the medications and underlying diseases of enrolled patients. Previous studies have revealed that patients taking proton pump inhibitors‍ ( 44 , 45 ) and patients with renal dysfunction‍ ( 46 ) showed significantly elevated serum PG. Such patients should have been excluded from the present study, but the present study did not have access to information on underlying diseases or medications and thus may well have included such patients.…”

Section: Discussionmentioning

confidence: 99%

Analysis of long-term serological and histological changes after eradication of <i>Helicobacter pylori</i>

Fukuda

Kodama

Mizukami

et al. 2022

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Stratification of gastric cancer risk by measuring serological biomarkers is useful for screening of gastric cancer. However, this method has problem such as overlooking past infected patients. We aimed to evaluate the association between Helicobacter pylori infection status and serological biomarkers. We divided 5,268 patients according to Helicobacter pylori infection status and past infected patients were divided into 12 groups according to time elapsed since eradication. We analyzed mean serum H. pylori immunoglobulin G antibody, pepsinogen titers, histological and endoscopic atrophy score of each group. Mean H. pylori immunoglobulin G antibody showed a decreasing tendency, there was no significant difference from the uninfected group at 11 years after eradication ( p = 0.19). PGI, PGII decreased in short term after eradication. However, both PGI and PGII gradually increased as long-term changes after eradication, became comparable to those in the uninfected group ( p = 0.41, p = 0.37, respectively). Histological atrophy improved gradually, became equivalent to uninfected group. Endoscopic atrophy score did not improve for long term after eradication. In conclusion, patients with long term after eradication reach the uninfected condition serologically, histologically. Endoscopic assessment of gastric mucosal atrophy may be useful for accurate assessment of gastric cancer risk.

show abstract

Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis

1993

View full text Add to dashboard Cite

Administration of omeprazole induces increases in serum concentrations of pepsinogens A and C. In 10 patients with reflux esophagitis who were on continuous maintenance treatment, the effect of cessation of omeprazole administration on serum pepsinogens was studied. Pepsinogens A and C were measured in serum samples on days 0, 1, 2, 4, 7, and 9 after treatment and the results were compared with the values available in eight patients at a time before omeprazole treatment. Serum pepsinogen A levels decreased gradually after cessation of omeprazole administration, and all values fell into the normal range after the seventh day of the study period, but were still higher than before therapy. Seven of 10 patients showed a decrease of pepsinogen C after nine days, but two patients had still increased levels at the end of the study period. The pepsinogen A:C ratio on the ninth day after cessation was significantly lower than on day 0 during omeprazole therapy. We conclude that long-term maintenance therapy with omeprazole induces significant increases in both serum pepsinogens. After cessation of omeprazole treatment, serum pepsinogens rapidly decrease in most patients, but continue to be higher before therapy for at least nine days.

show abstract

Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.

Cited by 5 publications

References 22 publications

Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels

Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels

Analysis of long-term serological and histological changes after eradication of <i>Helicobacter pylori</i>

Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis

Contact Info

Product

Resources

About